Background: Brain metastases are the most common intracranial tumour in adults, estimated to occur in up to 40% of patients with cancer. Despite being used in clinical practice for 50 years, the effectiveness of whole brain radiotherapy for the treatment of brain metastases remains uncertain.
Objectives: To assess the effectiveness of whole brain radiotherapy (WBRT) on survival and quality of life. To identify whether patient performance status, number of brain metastases, extent of extracranial disease and primary site of cancer are important effect modifiers.
Design: Systematic literature review.
Methods: Electronic searches of four databases, augmented by hand searches of the most frequently encountered journal and assessment of the reference lists of consensus statements and all retrieved papers. Included papers underwent structured data extraction, assessment and qualitative synthesis.
Results: Thirty-two primary studies were included, with a range of study designs, methodological quality, pre-treatment variables, interventions and outcome measures. From the limited evidence available, survival appeared to increase when patients were selected by performance status (survival increasing from approximately three to seven months in high performance status groups, as defined by Karnofsky performance status or Recursive Partitioning Analysis classification). The evidence suggests no survival benefit when patients with poor performance status were treated with whole brain radiotherapy. No studies undertook direct measurement of patients’ quality of life. Surrogate measures of patients’ quality of life, such as improvement in neurological function or improvement/maintenance of KPS] 70, produced response rates ranging from 7 to 90%.
Conclusion: The heterogeneity of study designs, quality and outcomes necessitates caution in interpreting the review findings. WBRT appears to be of benefit in higher performance status patients but not in low performance status patients. This suggests a basis for current practice, however further robust trial evidence is required.
Distefano A , Yap HY , Hortobagi GN , et al. The natural history of breast cancer patients with brain metastases . Cancer1979; 44: 1913–1918 .
2.
Cairncross JG , Posner JB . The metastases. In Walker MD ed. Oncology on the nervous system. Boston: Martinis Nijhoff , 1983: 341–770.
3.
Kofman S , Garvin JS , Nagamani D , et al. Treatment of cerebral metastases from breast cancer patients with prednisolone . JAMA1957; 163: 1473–1476 .
4.
Ruderman NB , Hall TC . Use of glucocorticoids in the palliative treatment of metastatic brain tumors . Cancer1965; 18: 298–306 .
5.
Hoskin PJ , Brada M . Consensus statement: radiotherapy for brain metastases . Clin Oncol2001; 13: 91–94 .
6.
Tsao MN , Sultanem K , Chiu D . Supportive care management of brain metastases: what is known and what we need to know . Clin Oncol2003; 15: 429–434 .
7.
Roesnberg W . How to ask clinical questions you can answer? In Sackett D , Richardson S , Rosenberg W , Haynes RB eds. Evidence-based medicine: how to practice and teach evidence based medicine, first edition. New York: Churchill Livingstone , 1997: 21–36.
8.
Simpson JR , Mendenhall WM , Schupak KD , et al. Follow-up and retreatment of brain metastasis. American College of Radiology. ACR appropriateness criteria . Radiology2000; 215Suppl: 1129–1135 .
9.
Edwards AE , Hood K , Matthews E , et al. The effectiveness on one-to-one risk-communication interventions in health care: a systematic review . Med Decis Making2000; 20: 290–297 .
10.
Phillips TL , Scott CB , Leibel SA , Rotman M , Weigensberg IJ . Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05 . Int J Radiat Oncol Biol Phys1995; 33: 339–3348 .
11.
Kormarnicky LT , Phillips TL , Martz K , Asbell S , Isaacson S , Urtasun R . A randomized phase III protocol for the evaluation of Misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG 7916) . Int J Radiat Oncol Biol Phys1991; 20: 53–58 .
12.
Sause WT , Scott C , Krisch R , et al. Phase I/II trail of accelerated fractionation in brain metastases RTOG 85-28 . Int J Radiat Oncol Biol Phys1993; 26: 653–657 .
13.
Gaspar L , Scott C , Rotman M , Asbell S , Phillips T , et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials . Int J Radiat Oncol Biol Phys1997; 37: 745–751 .
14.
Edwards A , Hailey S , Maxwell M . Psychological interventions for metastatic breast cancer (review). Cochrane Library , issue 2. 2004.
15.
Robinet G , Thomas P , Breton JL , et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastases of non-small-cell lung cancer: Group Francais de Pneumo Cancerologie (GFPC) Protocol 95-1 . Ann Oncol2001; 12: 59–67 .
16.
Chatani M , Teshima T , Hata K , Inoue T . Prognostic factors in patients with brain metastases from lung carcinoma . Strahlenthe Onkol1986; 162: 157–161 .
17.
Borgelt B , Gelber R , Kramer S , et al. The palliation of brain metastases: final results of the first two studies by the radiation therapy oncology group . Int J Radiat Oncol Biol Phys1980; 6: 1–9 .
18.
Borgelt B , Gelber R , Larson M , et al. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases. Final results of the first two studies by the Radiation Therapy Oncology Group . Int J Radiat Oncol Biol Phys1981; 7: 1633–1638 .
19.
Horton J , Baxter DH , Olson KB . The management of metastases to the brain by irradiation and corticosteroids . Am J Roentgenol Radium Ther Nucl Med1971; 111: 334–336 .
20.
Harwood A , Simpson W . Radiation therapy of cerebral metastases. A randomized prospective clinical trial . Int J Radiat Oncol Biol Phys1977; 2: 1091–1094 .
21.
Kurtz JM , Gelber R , Brady LW , Carella RJ , Cooper JS . The palliation of brain metastases in a favourable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group . Int J Radiat Oncol Biol Phys1981; 7: 891–895 .
22.
Mornex F , Thomas L , Mohr P , et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma . Melanoma Res2003; 13: 97–103 .
23.
Postmus P , Haaxma-Reiche H , Smit EF , et al. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy a phase III study of the European Organisation for the research and treatment of cancer. Lung Cancer Co-Operative Group . J Clin Oncol2000; 18: 3400–3408 .
24.
Priestman TJ , Dunn J , Brada M , Rampling R , Baker PG . Final results of the Royal College of Radiologists’ trial comparing two different radiotherapy schedules in the treatment of cerebral metastases . Clin Oncol1996; 8: 308–315 .
25.
Chatani M , Matayoski Y , Masaki N , Inoue T . Radiation therapy for brain metastases from lung carcinoma. Prospective randomized trial according to the level of lactate dehydrogenase . Strahlenther Onkol1994; 170: 155–161 .
26.
Haie-Meder C , Pellae-Cosset B , Laplanche A , Lagrange JL , Tuchais C, et al . Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases Radiother Oncol. 1993; 26: 111–116 .
27.
Kormarnicky LT , Phillips TL , Martz K , Asbell S , Isaacson S , Urtasun R . A randomized phase III protocol for the evaluation of Misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG 7916) . Int J Radiat Oncol Biol Phys1991; 20: 53–58 .
28.
Murray KJ , Scott C , Greenberg HM , et al. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the radiation therapy oncology group (RTOG) 9104 . Int J Radiat Oncol Biol Phys1997; 39: 571–574 .
29.
Murray KJ , Scott C , Zachariah B , et al. Importance of the mini-mental status examination in the treatment of patients with brain metastases: a report from the radiation therapy oncology group protocol 91-04 . Int J Radiat Oncol Biol Phys2000; 48: 59–64 .
30.
Li B , Yu J , Suntharalingham M , Kennedy AS , Amin PP , et al. Comparison of three treatment options for single brain metastasis from lung cancer . Int J Cancer2000; 90: 37–45 .
31.
Kondziolka D , Patel A , Lunsford LD , Kassam A , Flickinger JC . Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases . Int J Radiat Oncol Biol Phys1999; 45: 427–434 .
32.
Mintz AH , Kestle J , Rathbone MP , et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with single cerebral metastasis . Cancer1996; 78: 1470–1476 .
33.
Phillips TL , Scott CB , Leibel SA , Rotman M , Weigensberg IJ . Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: Report of RTOG trial 89-05 . Int J Radiat Oncol Biol Phys1995; 33: 339–348 .
34.
Noordijk EM , Vecht CJ , Haaxma-Reiche H , et al. The choice of treatment of single brain metastases should be based on extracranial tumor activity and age . Int J Radiat Oncol Biol Phys1994; 29: 711–717 .
35.
DeAngelis LM , Currie VE , Kim J-H , Krol G , O’Hehir MA , et al. The combined use of radiation therapy and lonidamine in the treatment of brain metastases . J Neuro-Oncol1989; 7: 241–247 .
36.
D’Elia F , Bonucci I , Biti GP , Pirtoli L . Different fractionation schedules in radiation treatment of cerebral metastases . Acta Radiol Oncol1986; 25: 181–184 .
37.
Patchell RA , Tibbs PA , Walsh JW , et al. A randomized trial of surgery in the treatment of single metastases to the brain . New Engl J Med1990; 322: 494–500 .
38.
Antonadou D , Paraskevaidis M , Sarria G , et al. Phase II randomized trial of Temozolamide and concurrent radiotherapy in patients with brain metastases . J Clin Oncol2002; 20: 3644–3650 .
39.
Mehta M , Rodrigus P , Terhaard C , et al. Survival and neurologic outcomes in a randomized trial of Motexafin Gadolinium and whole brain radiation therapy in brain metastases . J Clin Oncol2003; 21: 2529–2536 .
40.
Nieder C , Nestle U , Motaref B , et al. Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes?Int J Radiat Oncol Biol Phys2000; 46: 297–302 .
41.
Ampil FL , Burton GV , Mills GM . Cranial irradiation in patients with brain metastasis: a retrospective study of timing . Radiat. Med1999; 17: 271–273 .
42.
Wronski M , Maor MH , Davis BJ , Sawaya R , Levin VA . External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson cancer centre . Int J Radiat Oncol Biol Phys1997; 37: 753–759 .
43.
Bach F , Sorensen JB , Adrian L , Larsen H , Langer SW , et al. Brain relapses in chemotherapy-treated small-cell lung cancer: a retrospective review of two time-dose regimens of therapeutic brain irradiation . Lung Cancer1996; 15: 171–181 .
44.
Nieder C , Andratschke N , Grosu AL , Molls M . Recursive partitioning analysis (RPA) class does not predict survival in patients with four or more brain metastases . Strahlenther Onkol2003; 1: 16–20 .
45.
Mahmoud-Ahmed AS , Suh JH , Lee S-Y , Crownover RL , Barnett GH . Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study . Int J Radiat Oncol Biol Phys2002; 54: 810–817 .
46.
Lutterbach J , Bartelt S , Stancu E , Guttenberger R . Patients with brain metastases: hope for recursive partitioning analysis (RPA) class 3 . Radiother Oncol2002; 63: 339–345 .
47.
Gaspar L , Scott C , Murray K , Curran W . Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases . Int J Radiat Oncol Biol Phys2000; 47: 1001–1006 .
48.
Karnofsky D , Burchenal J . The clinical evaluation of chemotherapeutic agents in cancer. In Macleod CM ed. Evaluation of chemotherapeutic agents. New York: Columbia University Press , 1949: 196-196.
49.
Verger E , Salamero M , Carill C , et al. Eastern Cooperative Oncology Group – ECOG . Eur J Cancer1992; 28A89: 1328–1330 .
50.
WHO Handbook for reporting results of Cancer Treatment. 1979, WHO Offset Publication . No. 48: 7-7.
51.
Souhami RL , Tobias JS . Cancer and its management. Oxford: Blackwell1986: 180–201.
52.
Caraceni A , Martini C . Neurological problems. In Doyle D , Hanks GW , MacDonald N eds. Oxford Textbook of Palliative Medicine , second edition. 1999 Ch 9.12: 728-728.
53.
Higginson I , Finlay I , Goodwin D , et al. Do hospitalbased palliative teams improve care for patients or families at the end of life? (review). J Pain Symp Manage2002; 23: 96–106 .
